ERIS Lifescience

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE406M01024
  • NSEID: ERIS
  • BSEID: 540596
INR
1,319.50
-8.4 (-0.63%)
BSENSE

Nov 20

BSE+NSE Vol: 35.84 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy
Comparison
Company
Score
Quality
Valuation
Financial
Technical
Alembic Pharma
Rubicon Research
Alivus Life
Piramal Pharma
Granules India
Neuland Labs.
Shilpa Medicare
OneSource Speci.
ERIS Lifescience
Cohance Life
Pfizer
Why is ERIS Lifesciences Ltd ?
1
Poor long term growth as Operating profit has grown by an annual rate 16.01% of over the last 5 years
2
Stock is technically in a Mildly Bearish range
  • A key technical factor - KST has been Bearish since 05 Nov 2026
3
Underperformed the market in the last 1 year
  • Even though the market (BSE500) has generated returns of 0.37% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -21.06% returns
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is ERIS Lifescience for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
ERIS Lifescience
-21.06%
-0.70
30.24%
Sensex
-2.0%
-0.13
14.98%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
20.74%
EBIT Growth (5y)
16.01%
EBIT to Interest (avg)
9.33
Debt to EBITDA (avg)
2.00
Net Debt to Equity (avg)
0.52
Sales to Capital Employed (avg)
0.54
Tax Ratio
Tax Ratio is Negative%
Dividend Payout Ratio
28.45%
Pledged Shares
21.25%
Institutional Holding
25.94%
ROCE (avg)
14.94%
ROE (avg)
15.96%
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
24
Industry P/E
40
Price to Book Value
4.42
EV to EBIT
23.41
EV to EBITDA
17.65
EV to Capital Employed
3.24
EV to Sales
6.15
PEG Ratio
0.31
Dividend Yield
0.55%
ROCE (Latest)
13.85%
ROE (Latest)
18.25%
Loading Valuation Snapshot...
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Mildly Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
Mildly Bearish
OBV
Mildly Bullish
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

18What is working for the Company
PAT(Q)

At Rs 219.72 cr has Grown at 82.8%

DEBT-EQUITY RATIO(HY)

Lowest at 0.59 times

OPERATING PROFIT TO INTEREST(Q)

Highest at 6.66 times

NET SALES(Q)

Highest at Rs 892.37 cr

PBDIT(Q)

Highest at Rs 309.35 cr.

PBT LESS OI(Q)

Highest at Rs 188.61 cr.

-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 6.98 times

Loading Valuation Snapshot...
Here's what is working for ERIS Lifescience
Profit After Tax (PAT) - Quarterly
At Rs 219.72 cr has Grown at 82.8%
Year on Year (YoY)
MOJO Watch
Near term PAT trend is very positive

PAT (Rs Cr)

Operating Profit to Interest - Quarterly
Highest at 6.66 times
in the last five quarters
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Debt-Equity Ratio - Half Yearly
Lowest at 0.59 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Net Sales - Quarterly
Highest at Rs 892.37 cr
in the last five quarters
MOJO Watch
Near term sales trend is positive

Net Sales (Rs Cr)

Operating Profit (PBDIT) - Quarterly
Highest at Rs 309.35 cr.
in the last five quarters
MOJO Watch
Near term Operating Profit trend is positive

Operating Profit (Rs Cr)

Profit Before Tax less Other Income (PBT) - Quarterly
Highest at Rs 188.61 cr.
in the last five quarters
MOJO Watch
Near term PBT trend is positive

PBT less Other Income (Rs Cr)

Here's what is not working for ERIS Lifescience
Inventory Turnover Ratio- Half Yearly
Lowest at 6.98 times and Fallen
each half year in the last five half yearly periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Non Operating Income - Quarterly
Highest at Rs 3.20 cr
in the last five quarters
MOJO Watch
Increased income from non business activities may not be sustainable

Non Operating Income